Vertex Pharmaceuticals: The Ultimate Biotech Stock to Buy Now
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy VRTX?
Source: Fool
- Market Leadership: Vertex Pharmaceuticals is the leading player in the cystic fibrosis treatment market, having gained approval for its first drug in 2012, and now treats approximately 90% of CF patients, significantly enhancing patient quality of life and solidifying its market share.
- Ongoing Innovation: The company is developing a candidate to address cases that current drugs cannot treat, and with strong intellectual property and continuous innovation, Vertex is expected to maintain its leadership and achieve growth in the coming years.
- New Growth Drivers: Vertex received approvals for Casgevy for blood disorders in 2023 and Journavx for pain management in 2025, with non-CF products projected to generate at least $500 million in revenue this year, indicating strong market potential.
- Financial Outlook: The company forecasts total revenue of up to $13.1 billion this year, with the ongoing growth of its CF product portfolio providing robust support for its future financial performance, further enhancing its investment appeal in the biotech sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VRTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VRTX
Wall Street analysts forecast VRTX stock price to rise
22 Analyst Rating
17 Buy
5 Hold
0 Sell
Strong Buy
Current: 474.270
Low
414.00
Averages
515.88
High
604.00
Current: 474.270
Low
414.00
Averages
515.88
High
604.00
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of Gene Editing Drug Market Prospects
- Gene Editing Breakthrough: Vertex Pharmaceuticals' collaboration with CRISPR Therapeutics led to the approval of Casgevy, the first gene-editing drug targeting sickle cell disease and transfusion-dependent beta-thalassemia, marking a significant advancement in gene therapy, although market revenue remains limited.
- Cost Challenges: With a treatment cost of $2.2 million in the U.S., the complex administration process and high expenses make it difficult for insurance companies to adopt, thereby restricting market penetration and patient accessibility, impacting the widespread application of gene editing drugs.
- Market Competition Analysis: CRISPR Therapeutics currently has only Casgevy as its approved drug and continues to face net losses, while Vertex boasts a diverse product lineup that enables stable sales and profits, demonstrating stronger market competitiveness and investment appeal.
- Future Development Potential: While CRISPR Therapeutics presents high return opportunities, especially if its CTX310 drug is approved to rapidly improve treatment for high cholesterol patients, the associated clinical research risks are significant, making it suitable for investors with higher risk tolerance.
See More
Investment Outlook in Gene Editing Market
- CRISPR Challenges: CRISPR Therapeutics faces significant challenges as its revolutionary drug Casgevy, approved for treating rare blood disorders, has not generated substantial revenue due to its high treatment cost of $2.2 million and the fact that it only has one approved product, leading to ongoing net losses.
- Vertex's Robust Business: In contrast, Vertex Pharmaceuticals boasts a diverse product lineup that generates consistent sales and profits, making it a safer investment option, especially as gene-editing therapies struggle for widespread acceptance among insurers.
- Market Potential: CRISPR Therapeutics is developing CTX310, which could provide a rapid treatment for lowering LDL cholesterol; if successful, it could significantly boost the company's stock price over the next decade, despite the risk of clinical trial failures.
- Investor Risk Assessment: While CRISPR Therapeutics offers high upside potential, it also carries considerable volatility, making it suitable for risk-tolerant investors, whereas Vertex provides more stable returns, appealing to risk-averse investors.
See More
FDA Faces Criticism Amid Innovation Challenges
- Regulatory Standards Controversy: Congressman Jake Auchincloss criticized FDA Commissioner Marty Makary for replacing standards of safety and efficacy with fear and favoritism, undermining patient confidence in new therapies and impacting the market launch of innovative drugs.
- Staffing Losses: The FDA has experienced significant staff reductions in its Center for Drug Evaluation and Research, with oncology review staff dropping from about 100 to below 60, which may lead to approval delays and incomplete response letters.
- Decline in Accelerated Approvals: In 2024, the FDA approved 20 drugs through the accelerated approval process, down from 9 the previous year, indicating a direct impact on drug approval efficiency due to the loss of experienced reviewers.
- New Therapy Approval Pathways: The FDA proposed a new system for approving personalized drugs aimed at rare diseases, intending to provide more flexible approval pathways, but this change has sparked widespread controversy, affecting the agency's core mission.
See More
CRISPR Therapeutics: Potential and Challenges in Gene Editing
- Therapeutic Progress: CRISPR's gene-editing therapy Casgevy was approved in 2023 for treating sickle cell disease and transfusion-dependent beta thalassemia, showcasing its revolutionary potential in healthcare.
- High Treatment Costs: Despite Casgevy's staggering price of $2.2 million, healthcare experts justify this cost due to its one-time treatment nature, which could save patients time and money in the long run.
- Financial Challenges: CRISPR reported a net loss of $581.6 million in 2025, an increase from the $366.3 million loss in 2024, highlighting the significant expenditure pressures the company faces as it rolls out Casgevy.
- Strong Cash Position: As of the end of last year, CRISPR had approximately $2 billion in cash and marketable securities, indicating that despite its losses, the company is not at immediate risk of running out of funds, maintaining long-term growth potential.
See More
CRISPR Therapeutics Faces Significant Challenges Amid Slow Rollout
- Escalating Financial Losses: CRISPR reported a net loss exceeding $580 million in 2025, a significant increase from the $366.3 million loss in 2024, highlighting the pressure from high expenditures during the rollout of the Casgevy treatment and ongoing financial struggles.
- Strong Cash Position: Despite the losses, CRISPR maintained approximately $2 billion in cash and marketable securities at the end of last year, which is sufficient to support its daily operations, having consumed $345 million in 2025, indicating that the company is not at immediate risk of running out of funds.
- Slow Product Rollout: Although Casgevy was approved in 2023 and patient initiations nearly tripled last year, its staggering price of $2.2 million and profit-sharing with Vertex Pharmaceuticals limit CRISPR's market earnings, adversely affecting its profitability.
- Uncertain Market Outlook: While CRISPR's gene-editing therapies hold long-term potential, the lack of current profitability and the risk assessment of its stock make it a cautious buy for investors, especially as it was not included in the list of top recommended stocks by analysts.
See More
Vertex Pharmaceuticals Officer Plans to Sell $19.74 Million in Common Stock via Form 144
Stock Sale Announcement: Kewalramani, an officer at Vertex Pharmaceuticals, plans to sell 40,000 shares of the company's common stock.
Market Value: The total market value of the shares being sold is approximately $19.74 million.
See More
Analysis of Gene Editing Drug Market Prospects
- Gene Editing Breakthrough: Vertex Pharmaceuticals' collaboration with CRISPR Therapeutics led to the approval of Casgevy, the first gene-editing drug targeting sickle cell disease and transfusion-dependent beta-thalassemia, marking a significant advancement in gene therapy, although market revenue remains limited.
- Cost Challenges: With a treatment cost of $2.2 million in the U.S., the complex administration process and high expenses make it difficult for insurance companies to adopt, thereby restricting market penetration and patient accessibility, impacting the widespread application of gene editing drugs.
- Market Competition Analysis: CRISPR Therapeutics currently has only Casgevy as its approved drug and continues to face net losses, while Vertex boasts a diverse product lineup that enables stable sales and profits, demonstrating stronger market competitiveness and investment appeal.
- Future Development Potential: While CRISPR Therapeutics presents high return opportunities, especially if its CTX310 drug is approved to rapidly improve treatment for high cholesterol patients, the associated clinical research risks are significant, making it suitable for investors with higher risk tolerance.
See More
Investment Outlook in Gene Editing Market
- CRISPR Challenges: CRISPR Therapeutics faces significant challenges as its revolutionary drug Casgevy, approved for treating rare blood disorders, has not generated substantial revenue due to its high treatment cost of $2.2 million and the fact that it only has one approved product, leading to ongoing net losses.
- Vertex's Robust Business: In contrast, Vertex Pharmaceuticals boasts a diverse product lineup that generates consistent sales and profits, making it a safer investment option, especially as gene-editing therapies struggle for widespread acceptance among insurers.
- Market Potential: CRISPR Therapeutics is developing CTX310, which could provide a rapid treatment for lowering LDL cholesterol; if successful, it could significantly boost the company's stock price over the next decade, despite the risk of clinical trial failures.
- Investor Risk Assessment: While CRISPR Therapeutics offers high upside potential, it also carries considerable volatility, making it suitable for risk-tolerant investors, whereas Vertex provides more stable returns, appealing to risk-averse investors.
See More
FDA Faces Criticism Amid Innovation Challenges
- Regulatory Standards Controversy: Congressman Jake Auchincloss criticized FDA Commissioner Marty Makary for replacing standards of safety and efficacy with fear and favoritism, undermining patient confidence in new therapies and impacting the market launch of innovative drugs.
- Staffing Losses: The FDA has experienced significant staff reductions in its Center for Drug Evaluation and Research, with oncology review staff dropping from about 100 to below 60, which may lead to approval delays and incomplete response letters.
- Decline in Accelerated Approvals: In 2024, the FDA approved 20 drugs through the accelerated approval process, down from 9 the previous year, indicating a direct impact on drug approval efficiency due to the loss of experienced reviewers.
- New Therapy Approval Pathways: The FDA proposed a new system for approving personalized drugs aimed at rare diseases, intending to provide more flexible approval pathways, but this change has sparked widespread controversy, affecting the agency's core mission.
See More
CRISPR Therapeutics: Potential and Challenges in Gene Editing
- Therapeutic Progress: CRISPR's gene-editing therapy Casgevy was approved in 2023 for treating sickle cell disease and transfusion-dependent beta thalassemia, showcasing its revolutionary potential in healthcare.
- High Treatment Costs: Despite Casgevy's staggering price of $2.2 million, healthcare experts justify this cost due to its one-time treatment nature, which could save patients time and money in the long run.
- Financial Challenges: CRISPR reported a net loss of $581.6 million in 2025, an increase from the $366.3 million loss in 2024, highlighting the significant expenditure pressures the company faces as it rolls out Casgevy.
- Strong Cash Position: As of the end of last year, CRISPR had approximately $2 billion in cash and marketable securities, indicating that despite its losses, the company is not at immediate risk of running out of funds, maintaining long-term growth potential.
See More
CRISPR Therapeutics Faces Significant Challenges Amid Slow Rollout
- Escalating Financial Losses: CRISPR reported a net loss exceeding $580 million in 2025, a significant increase from the $366.3 million loss in 2024, highlighting the pressure from high expenditures during the rollout of the Casgevy treatment and ongoing financial struggles.
- Strong Cash Position: Despite the losses, CRISPR maintained approximately $2 billion in cash and marketable securities at the end of last year, which is sufficient to support its daily operations, having consumed $345 million in 2025, indicating that the company is not at immediate risk of running out of funds.
- Slow Product Rollout: Although Casgevy was approved in 2023 and patient initiations nearly tripled last year, its staggering price of $2.2 million and profit-sharing with Vertex Pharmaceuticals limit CRISPR's market earnings, adversely affecting its profitability.
- Uncertain Market Outlook: While CRISPR's gene-editing therapies hold long-term potential, the lack of current profitability and the risk assessment of its stock make it a cautious buy for investors, especially as it was not included in the list of top recommended stocks by analysts.
See More
Vertex Pharmaceuticals Officer Plans to Sell $19.74 Million in Common Stock via Form 144
Stock Sale Announcement: Kewalramani, an officer at Vertex Pharmaceuticals, plans to sell 40,000 shares of the company's common stock.
Market Value: The total market value of the shares being sold is approximately $19.74 million.
See More
